PrEP choice in the real world: Results of a prospective cohort study describing uptake and use patterns of oral PrEP and the dapivirine vaginal ring among women in sub-Saharan Africa

IF 4.9 1区 医学 Q2 IMMUNOLOGY
Virginia A. Fonner, Elizabeth Irungu, Mark Conlon, Carolyne A. Akello, Emily Gwavava, Kevin K'Orimba, Nicolette P. Naidoo, Patriciah Jeckonia, Imelda Mahaka, Saiqa Mullick, Mamatli Chabela, Roisin Drysdale, Jacqueline Kabongo, Millicent Kiruki, Ivan Segawa, Munyaradzi Dobbie, Nthuseng Marake, Peter Mudiope, Hasina Subedar, Rose Wafula, Andrew Kazibwe, Jason Reed, Katharine Kripke, Douglas Taylor, Mu-Tien Lee, Glory Chidumwa, Adatia Chivafa, Ramatsoai Soothoane, Margaret Eichleay, Ashley Mayo, Courtney McGuire, Tara McClure, Tatenda Yemeke, Kristine Torjesen, the CATALYST study team
{"title":"PrEP choice in the real world: Results of a prospective cohort study describing uptake and use patterns of oral PrEP and the dapivirine vaginal ring among women in sub-Saharan Africa","authors":"Virginia A. Fonner,&nbsp;Elizabeth Irungu,&nbsp;Mark Conlon,&nbsp;Carolyne A. Akello,&nbsp;Emily Gwavava,&nbsp;Kevin K'Orimba,&nbsp;Nicolette P. Naidoo,&nbsp;Patriciah Jeckonia,&nbsp;Imelda Mahaka,&nbsp;Saiqa Mullick,&nbsp;Mamatli Chabela,&nbsp;Roisin Drysdale,&nbsp;Jacqueline Kabongo,&nbsp;Millicent Kiruki,&nbsp;Ivan Segawa,&nbsp;Munyaradzi Dobbie,&nbsp;Nthuseng Marake,&nbsp;Peter Mudiope,&nbsp;Hasina Subedar,&nbsp;Rose Wafula,&nbsp;Andrew Kazibwe,&nbsp;Jason Reed,&nbsp;Katharine Kripke,&nbsp;Douglas Taylor,&nbsp;Mu-Tien Lee,&nbsp;Glory Chidumwa,&nbsp;Adatia Chivafa,&nbsp;Ramatsoai Soothoane,&nbsp;Margaret Eichleay,&nbsp;Ashley Mayo,&nbsp;Courtney McGuire,&nbsp;Tara McClure,&nbsp;Tatenda Yemeke,&nbsp;Kristine Torjesen,&nbsp;the CATALYST study team","doi":"10.1002/jia2.26457","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>HIV incidence remains high among women in Africa, especially adolescent girls and young women (AGYW), despite existing oral pre-exposure prophylaxis (PrEP) programmes. With expanding biomedical prevention options, understanding PrEP use patterns when women are offered choice can inform HIV prevention programming in Africa.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The CATALYST study offers informed PrEP choice through an enhanced service delivery package for women in 27 public health sites across Kenya, Lesotho, South Africa, Uganda, and Zimbabwe. Women attending sites who were HIV negative and interested in learning about HIV prevention were eligible. We describe uptake and use among those offered choice between oral PrEP and the monthly dapivirine ring from May 2023 through July 2024, explore factors associated with method choice using logistic regression, describe reasons for choice and assess time until PrEP discontinuation using survival analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 3967 participants, 44.9% were AGYW (15−24 years), 25.5% were sex workers, and 12.2% and 8.7% were breastfeeding and/or pregnant, respectively. At enrolment, 66.2% chose oral PrEP, 29.9% chose the dapivirine ring and 3.5% chose no method. Common reasons for choosing oral PrEP were ease of use (58.6%) and efficacy (31.7%); the ring was chosen due to ease of use (56.9%) and not needing to swallow pills (53.0%). In multivariable analysis, participants ≤ 24 years (<i>p</i> = 0.007) and participants who were pregnant (<i>p</i> = 0.002) or breastfeeding (<i>p</i> &lt; 0.001) had lower odds of choosing the ring. Month 1 return was 32.7% for oral PrEP and 55.2% for the ring. Ring users reported higher adherence as compared to oral PrEP users (<i>p</i> &lt; 0.001). Of participants returning for ≥ 1 PrEP refills, 12.1% switched methods at least once. Median time until PrEP discontinuation was 95 days (95% CI: 91, 110) for those choosing oral PrEP at enrolment and 169 days (95% CI: 139, 190) for those choosing the ring. Risk of discontinuation was greater for participants choosing oral PrEP at enrolment (<i>p</i> &lt; 0.001) and those ≤ 24 years (<i>p</i> &lt; 0.001), PrEP naïve at enrolment (<i>p</i> &lt; 0.001) or not currently using contraception (<i>p</i> = 0.03).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>We demonstrated that women took advantage of PrEP choice. PrEP use varied by product, with 1 month return and method continuation higher for the ring. AGYW had a greater risk of discontinuing either method, suggesting more support is needed.</p>\n </section>\n </div>","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"28 S2","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jia2.26457","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International AIDS Society","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jia2.26457","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

HIV incidence remains high among women in Africa, especially adolescent girls and young women (AGYW), despite existing oral pre-exposure prophylaxis (PrEP) programmes. With expanding biomedical prevention options, understanding PrEP use patterns when women are offered choice can inform HIV prevention programming in Africa.

Methods

The CATALYST study offers informed PrEP choice through an enhanced service delivery package for women in 27 public health sites across Kenya, Lesotho, South Africa, Uganda, and Zimbabwe. Women attending sites who were HIV negative and interested in learning about HIV prevention were eligible. We describe uptake and use among those offered choice between oral PrEP and the monthly dapivirine ring from May 2023 through July 2024, explore factors associated with method choice using logistic regression, describe reasons for choice and assess time until PrEP discontinuation using survival analysis.

Results

Of 3967 participants, 44.9% were AGYW (15−24 years), 25.5% were sex workers, and 12.2% and 8.7% were breastfeeding and/or pregnant, respectively. At enrolment, 66.2% chose oral PrEP, 29.9% chose the dapivirine ring and 3.5% chose no method. Common reasons for choosing oral PrEP were ease of use (58.6%) and efficacy (31.7%); the ring was chosen due to ease of use (56.9%) and not needing to swallow pills (53.0%). In multivariable analysis, participants ≤ 24 years (p = 0.007) and participants who were pregnant (p = 0.002) or breastfeeding (p < 0.001) had lower odds of choosing the ring. Month 1 return was 32.7% for oral PrEP and 55.2% for the ring. Ring users reported higher adherence as compared to oral PrEP users (p < 0.001). Of participants returning for ≥ 1 PrEP refills, 12.1% switched methods at least once. Median time until PrEP discontinuation was 95 days (95% CI: 91, 110) for those choosing oral PrEP at enrolment and 169 days (95% CI: 139, 190) for those choosing the ring. Risk of discontinuation was greater for participants choosing oral PrEP at enrolment (p < 0.001) and those ≤ 24 years (p < 0.001), PrEP naïve at enrolment (p < 0.001) or not currently using contraception (p = 0.03).

Conclusions

We demonstrated that women took advantage of PrEP choice. PrEP use varied by product, with 1 month return and method continuation higher for the ring. AGYW had a greater risk of discontinuing either method, suggesting more support is needed.

Abstract Image

现实世界中的PrEP选择:一项前瞻性队列研究的结果描述了撒哈拉以南非洲妇女口服PrEP和达匹维林阴道环的吸收和使用模式
导言非洲妇女,特别是少女和年轻妇女的艾滋病毒发病率仍然很高,尽管已有口服暴露前预防规划。随着生物医学预防方案的扩大,在向妇女提供选择的情况下,了解PrEP的使用模式可以为非洲的艾滋病毒预防规划提供信息。方法CATALYST研究通过在肯尼亚、莱索托、南非、乌干达和津巴布韦的27个公共卫生站点为妇女提供强化的服务方案,提供知情的PrEP选择。参加网站的妇女如果是艾滋病毒阴性并且有兴趣了解艾滋病毒预防,就有资格。我们描述了从2023年5月至2024年7月在口服PrEP和每月一次的达匹维林环之间进行选择的患者的摄取和使用情况,使用逻辑回归探讨了与方法选择相关的因素,描述了选择的原因,并使用生存分析评估了PrEP停止使用的时间。结果在3967名参与者中,44.9%为老年妇女(15 - 24岁),25.5%为性工作者,12.2%和8.7%分别为母乳喂养和/或怀孕。入组时,66.2%选择口服PrEP, 29.9%选择达匹韦林环,3.5%选择无方法。选择口服PrEP的常见原因是易用性(58.6%)和有效性(31.7%);选择环是因为使用方便(56.9%),不需要吞药(53.0%)。在多变量分析中,≤24岁(p = 0.007)和怀孕(p = 0.002)或母乳喂养(p <;0.001)选择戒指的几率较低。第1个月口服PrEP的回报率为32.7%,环的回报率为55.2%。与口服PrEP使用者相比,环使用者报告了更高的依从性(p <;0.001)。在返回进行≥1次PrEP补充的参与者中,12.1%的人至少转换了一次方法。入组时选择口服PrEP的患者停止PrEP的中位时间为95天(95% CI: 91, 110),选择环治疗的患者停止PrEP的中位时间为169天(95% CI: 139, 190)。在入组时选择口服PrEP的受试者停药的风险更大(p <;0.001)和≤24岁(p <;0.001),入组时PrEP naïve (p <;0.001)或目前没有使用避孕措施(p = 0.03)。结论:我们证明了妇女选择PrEP的优势。PrEP的使用因产品而异,1个月的回报和环的方法持续时间较高。AGYW停止使用任何一种方法的风险都更大,这表明需要更多的支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of the International AIDS Society
Journal of the International AIDS Society IMMUNOLOGY-INFECTIOUS DISEASES
CiteScore
8.60
自引率
10.00%
发文量
186
审稿时长
>12 weeks
期刊介绍: The Journal of the International AIDS Society (JIAS) is a peer-reviewed and Open Access journal for the generation and dissemination of evidence from a wide range of disciplines: basic and biomedical sciences; behavioural sciences; epidemiology; clinical sciences; health economics and health policy; operations research and implementation sciences; and social sciences and humanities. Submission of HIV research carried out in low- and middle-income countries is strongly encouraged.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信